Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Find out which cash back cards offer the best options for 2023. Stay updated with the latest offerings to maximize your rewards.
26,992 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
In a market obsessed with the next AI breakthrough, one stock stands out not for hype but for real, lasting traction....
Investors are testing a new approach to fund life’s milestones—without tapping the core retirement nest egg. The cele...
Adobe faces a dynamic year as AI competition and enterprise spending shape the adobe (adbe) stock price. This report ...
Argan stock ascended today as investors cheered stronger profits and a brighter outlook for energy infrastructure tie...
A big multi-system order helped Camtek push its stock higher as investors weighed the implications for backlog, margi...
VGIT remains a stable Treasury income option as yields swing with policy signals. This report analyzes how duration r...
tech stocks led a broad rally as Nvidia fueled AI optimism. This look at the stock market today, feb., explains what...
Amazon launches a $200 billion AI-focused capex plan for 2026, with Trainium and Anthropic in the mix. Here’s what in...
Bitmine reports a week of heavy ETH buying, boosting its holdings to about 4.59% of all ETH. The move comes alongside...
Broadcom’s custom silicon advantage dominates the AI hardware beat, delivering outsized revenue growth while Marvell ...
When building a portfolio, you face a choice between global exposure and an emerging markets tilt. This guide breaks ...